Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors

Journal Article · · Virology
;  [1]; ; ;  [1];  [2];  [3];  [4];  [1];  [1]
  1. Div. of Cellular and Molecular Therapy, Dept. of Pediatrics, Powell Gene Therapy Center, Univ. of Florida College of Medicine, Gainesville, FL 32610 (United States)
  2. Eli Lilly and Company, Indianapolis, IN 46285 (United States)
  3. Dept. of Microbiology and Immunology, Indiana Univ. School of Medicine, Indianapolis, IN 46202 (United States)
  4. Herman B Wells Center for Pediatric Research and Dept. of Biochemistry and Molecular Biology, Indiana Univ. School of Medicine, Indianapolis, IN 46202 (United States)

We have reported that tyrosine-phosphorylated forms of a cellular protein, FKBP52, inhibit the second-strand DNA synthesis of adeno-associated virus 2 (AAV), leading to inefficient transgene expression from recombinant AAV vectors. To further explore the role of FKBP52 in AAV-mediated transduction, we established murine embryo fibroblasts (MEFs) cultures from FKBP52 wild-type (WT), heterozygous (HE), and knockout (KO) mice. Conventional AAV vectors failed to transduce WT MEFs efficiently, and the transduction efficiency was not significantly increased in HE or KO MEFs. AAV vectors failed to traffic efficiently to the nucleus in these cells. Treatment with hydroxyurea (HU) increased the transduction efficiency of conventional AAV vectors by {approx}25-fold in WT MEFs, but only by {approx}4-fold in KO MEFs. The use of self-complementary AAV (scAAV) vectors, which bypass the requirement of viral second-strand DNA synthesis, revealed that HU treatment increased the transduction efficiency {approx}23-fold in WT MEFs, but only {approx}4-fold in KO MEFs, indicating that the lack of HU treatment-mediated increase in KO MEFs was not due to failure of AAV to undergo viral second-strand DNA synthesis. Following HU treatment, {approx}59% of AAV genomes were present in the nuclear fraction from WT MEFs, but only {approx}28% in KO MEFs, indicating that the pathway by which HU treatment mediates nuclear transport of AAV was impaired in KO MEFs. When KO MEFs were stably transfected with an FKBP52 expression plasmid, HU treatment-mediated increase in the transduction efficiency was restored in these cells, which correlated directly with improved intracellular trafficking. Intact AAV particles were also shown to interact with FKBP52 as well as with dynein, a known cellular protein involved in AAV trafficking. These studies suggest that FKBP52, being a cellular chaperone protein, facilitates intracellular trafficking of AAV, which has implications in the optimal use of recombinant AAV vectors in human gene therapy.

OSTI ID:
20850563
Journal Information:
Virology, Journal Name: Virology Journal Issue: 2 Vol. 353; ISSN VIRLAX; ISSN 0042-6822
Country of Publication:
United States
Language:
English

Similar Records

Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression
Journal Article · Mon Nov 24 23:00:00 EST 2008 · Virology · OSTI ID:21182784

Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells
Journal Article · Wed Nov 14 23:00:00 EST 2018 · Experimental Cell Research · OSTI ID:23082548

Adeno-associated virus rep protein synthesis during productive infection
Journal Article · Tue Jan 31 23:00:00 EST 1989 · J. Virol.; (United States) · OSTI ID:5822140